☆ 4.8 Article

Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Related references

Note: Only part of the references are listed.

Article Transplantation

Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients

Masaomi Nangaku et al.

Summary: The results of the studies support the development of vadadustat for the treatment of anemia in patients with CKD, showing significant efficacy in increasing Hb levels and adjusting iron utilization and mobilization. The incidence of adverse events during the primary efficacy period was similar to or slightly higher than the placebo group, with common events including nausea, hypertension, diarrhea, and nasopharyngitis.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Add to Collection

Article Medicine, General & Internal

Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD

Glenn M. Chertow et al.

Summary: Vadadustat, compared to darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not for cardiovascular safety in patients with NDD-CKD.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Transplantation

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials

Kai-Uwe Eckardt et al.

Summary: The INNO(2)VATE programme consists of two studies to evaluate the safety and efficacy of vadadustat versus the ESA darbepoetin alfa in ameliorating anaemia in patients with dialysis-dependent CKD. The demographics and baseline characteristics of enrolled patients suggest that the study results will be representative for a large proportion of the DD-CKD population.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Add to Collection

Article Transplantation

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents

Volker H. Haase et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)

Add to Collection

Article Medicine, General & Internal

Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis

N. Chen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Urology & Nephrology

Mechanisms of hypoxia signalling: new implications for nephrology

Johannes Schoedel et al.

NATURE REVIEWS NEPHROLOGY (2019)

Add to Collection

Review Urology & Nephrology

Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease

Mai Sugahara et al.

KIDNEY INTERNATIONAL (2017)

Add to Collection

Article Urology & Nephrology

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease

Edouard R. Martin et al.

AMERICAN JOURNAL OF NEPHROLOGY (2017)

Add to Collection

Review Urology & Nephrology

HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond

Patrick H. Maxwell et al.

NATURE REVIEWS NEPHROLOGY (2016)

Add to Collection

Article Urology & Nephrology

Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease

Pablo E. Pergola et al.

KIDNEY INTERNATIONAL (2016)

Add to Collection

Review Urology & Nephrology

Anaemia in kidney disease: harnessing hypoxia responses for therapy

Mark J. Koury et al.

NATURE REVIEWS NEPHROLOGY (2015)

Add to Collection

Review Hematology

Regulation of erythropoiesis by hypoxia-inducible factors

Volker H. Haase

BLOOD REVIEWS (2013)

Add to Collection

Review Biochemistry & Molecular Biology

Hypoxia-Inducible Factors in Physiology and Medicine

Gregg L. Semenza

CELL (2012)

Add to Collection

Article Urology & Nephrology

Mechanisms of Anemia in CKD

Jodie L. Babitt et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)

Add to Collection

Article Urology & Nephrology

Notice

Kidney International Supplements (2012)

Add to Collection

Article Urology & Nephrology

Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD

Wanja M. Bernhardt et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)

Add to Collection

Article Medicine, General & Internal

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Marc A. Pfeffer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

Review Biochemistry & Molecular Biology

Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway

William G. Kaelin et al.

MOLECULAR CELL (2008)

Add to Collection

Article Transplantation

Pharmacology of darbepoetin alfa

Iain C. Macdougall et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)

Add to Collection

Article Medicine, General & Internal

Correction of anemia with epoetin alfa in chronic kidney disease

Ajay K. Singh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Cardiac & Cardiovascular Systems

Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

TCH Mix et al.

AMERICAN HEART JOURNAL (2005)

Add to Collection

Article Transplantation

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)

F Locatelli et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.